| Title |
Cardiovascular risk, hypertension, and NSAIDs
|
|---|---|
| Published in |
Current Rheumatology Reports, June 2007
|
| DOI | 10.1007/s11926-007-0020-3 |
| Pubmed ID | |
| Authors |
William B. White |
| Abstract |
During the past 2 years, a great deal of evaluation has been conducted on the cardiovascular (CV) effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors. This review focuses on the effects of the NSAIDs and COX-2 inhibitors on blood pressure and CV events. Clinical trial databases for NSAIDs and COX-2 inhibitors have shown varying levels of destabilization of blood pressure control in treated hypertensive patients as well as variable incident rates of the development of arrhythmias, congestive heart failure, myocardial infarction, and stroke. Nonselective and COX-2 selective NSAIDs can be used carefully in arthritis patients with hypertension and stable CV disorders (excluding congestive heart failure and moderate to severe kidney dysfunction) when the individual clinical benefit of anti-inflammatory therapy outweighs the CV and gastrointestinal risk. |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 33% |
| Student > Master | 3 | 14% |
| Student > Ph. D. Student | 3 | 14% |
| Student > Postgraduate | 2 | 10% |
| Professor | 2 | 10% |
| Other | 1 | 5% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 48% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
| Agricultural and Biological Sciences | 2 | 10% |
| Immunology and Microbiology | 1 | 5% |
| Environmental Science | 1 | 5% |
| Other | 2 | 10% |
| Unknown | 3 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2023.
All research outputs
#8,386,366
of 25,058,309 outputs
Outputs from Current Rheumatology Reports
#300
of 747 outputs
Outputs of similar age
#28,363
of 79,665 outputs
Outputs of similar age from Current Rheumatology Reports
#1
of 4 outputs
Altmetric has tracked 25,058,309 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 747 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 79,665 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them